Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.51 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.48 |
| ▸ | CECR2 | Q9BXF3 | 4/20 | 0.44 |
| ▸ | TAF1 | P21675 | 3/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329893 | 0.85 | BRD4 (0.59) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL20385458 | 0.84 | BRD9 (0.48) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL19871750 | 0.74 | BRD4 (0.55) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22600098 | 0.73 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22516602 | 0.73 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL15069208 | 0.73 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL24556455 | 0.71 | BRD4 (0.56) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL31590544 | 0.71 | BRD4 (0.65) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL31590651 | 0.71 | BRD4 (0.66) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22729820 | 0.70 | BRD4 (0.42) | BRD4BRD9CECR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | BRD4 1170/4885BRD9 2497/4885CECR2 1109/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | BRD4 1201/4885BRD9 2508/4885CECR2 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.